Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
about
Antiviral drugs for viruses other than human immunodeficiency virusCMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant RecipientsCMV: Prevention, Diagnosis and TherapyClinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationDirect and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney TransplantationInfections after orthotopic liver transplantationAntiviral drug resistance: mechanisms and clinical implicationsCurrent concepts on cytomegalovirus infection after liver transplantationPost-transplant infections: An ounce of prevention.T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.Ganciclovir-resistant cytomegalovirus infection in renal transplantation.Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation.Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.IL-12-Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control.Cytomegalovirus infections in solid organ transplantation: a review.Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.CMV infection, diagnosis and antiviral strategies after liver transplantation.γδ T Cell-Mediated Immunity to Cytomegalovirus Infection.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Strategies for managing cytomegalovirus in transplant recipients.Management of viral infections in solid organ transplant recipients.Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus.Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Cytomegalovirus infection in lung transplant recipients.Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.Risk Factors and Outcomes of Ganciclovir Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin.Incidence of Ganciclovir Resistance in CMV-positive Renal Transplant Recipients and its Association with UL97 Gene Mutations.Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation.Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.Cytomegalovirus infection after liver transplantation: current concepts and challenges.Kinetics of host immune responses and cytomegalovirus resistance in a liver transplant patient.Management of cytomegalovirus infection in haemopoietic stem cell transplantation.
P2860
Q24635330-4685078B-EA88-4A28-AAF2-DE6DDF4B3CE0Q26768473-E1496542-8B67-4C16-B73A-AB635EC8498FQ26824869-F42DD27C-4026-45A6-911B-5F4D40808825Q26826856-AC717D5C-4F0A-4B54-8C46-B5A8AE4C0E3CQ26863724-86FADEF7-A4CC-435C-8024-31C7C450D99CQ27023182-B2247EA0-D8D8-4353-AC3D-0E67497AC373Q28282376-D2ECFF9C-CD6A-4192-96D1-22E39F1B5254Q34390310-81658917-971D-49A9-9BD2-4CC7E4AABEEBQ34435191-597F1C32-9FAA-4EDE-8D93-C2A797BB9D9DQ34550760-1B6A8E1F-091F-4A3D-A833-44A9C38AB62EQ35227636-2E1F7E7D-B8B0-439B-B6E6-3E9265FB4F8CQ35282503-7632AA9B-5C7A-41DF-B72D-F4FC246DC592Q35592509-CB41F0FF-E594-4697-AE45-3E0C1C4D9AFDQ36447548-20824B4F-E08E-48AD-980D-EDE29F79CF1EQ37359332-06C2C1FC-2FFD-41D0-9FF7-17EA4FCA0D49Q37544353-D9E4EC0F-D373-47BC-98C8-07CC7137AAF3Q37556586-12EC8DAE-0E0C-4605-8664-CBCDC0D5DD8BQ37632938-75BCD6F7-E7B4-4282-88DD-A9B1805055F1Q37680941-42E46292-5DD2-436F-92EC-17A5CDEC1E73Q37773992-5EE41414-ED08-4D26-827D-078A4B2C195DQ37892559-E218FBC0-F361-44A3-AD2E-DFAD089113C2Q37962447-00DFCF5A-E73F-46A3-A86A-83F28E873A0AQ38067694-5FDEAC3F-28D6-4100-9A3F-DB7CFF454B79Q38364698-A015C6ED-CC49-4961-B9D5-FECD4B0E9DECQ38370342-3DB57ACC-457E-4BAB-81B2-FE23AB7B22C3Q38415861-622CBDBD-9E53-4A54-9ADF-3447A821A5B5Q38664637-014C83FA-C6DF-42C2-B52C-9F5E46FEBED8Q38725677-9B619B00-C812-4B7C-B482-5B34CD858022Q38875887-927ACB32-DA8E-4DF7-A104-E1D0208A9A91Q39226830-D3BE5F8F-F62A-4DFD-B1DC-1DE64D1B3C13Q39502888-2F865282-2E69-4A9D-836A-23A47913DA8DQ40262029-693DAC68-3726-4B6C-A81F-FECA2C79AA02Q40426465-CB0F3337-5872-454F-ABC4-8C587E61FAEEQ40745646-E29FE7A9-344F-4A76-8961-9B4711BAA98EQ41923977-0A5872DD-FC75-4F41-98A3-F15D4C1D18A9Q42202589-2B2FACA4-9518-4E9E-B4CB-EB17AE04E6B3Q42259440-2E6C2EF9-AD0D-48A9-8179-AD0F7B2A7537Q42549311-D6F1AEAB-62C6-4126-896B-2E1EE1E7286AQ43269349-2908C9F9-9178-4402-B10F-10304B203069Q44714539-C9C05F91-663F-4F59-82C8-973BE0348CF9
P2860
Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Emergence of drug-resistant cy ...... tic implications and outcomes.
@en
Emergence of drug-resistant cy ...... tic implications and outcomes.
@nl
type
label
Emergence of drug-resistant cy ...... tic implications and outcomes.
@en
Emergence of drug-resistant cy ...... tic implications and outcomes.
@nl
prefLabel
Emergence of drug-resistant cy ...... tic implications and outcomes.
@en
Emergence of drug-resistant cy ...... tic implications and outcomes.
@nl
P2093
P1476
Emergence of drug-resistant cy ...... tic implications and outcomes.
@en
P2093
Albert J Eid
Mark P Wilhelm
Paul J Deziel
Raymund R Razonable
Supha K Arthurs
P304
P356
10.1111/J.1399-0012.2007.00761.X
P577
2008-03-01T00:00:00Z